| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
20,430,000 |
| Market
Cap: |
1.37(B) |
| Last
Volume: |
2,387,520 |
Avg
Vol: |
2,380,888 |
| 52
Week Range: |
$38.04 - $69.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ANI Pharmaceuticals is a bio-pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Co.'s products include: Candesartan Hydrochlorothiazide, Fenofibrate, Fluvoxamine, Hydrocortisone Enema, Lithium Carbonate ER, Mesalamine, Propranolol ER, Terbutaline, and Vancomycin.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
254,921 |
421,551 |
1,262,027 |
1,480,093 |
| Total Sell Value |
$16,747,919 |
$26,516,522 |
$74,515,877 |
$82,888,946 |
| Total People Sold |
8 |
9 |
12 |
12 |
| Total Sell Transactions |
23 |
40 |
87 |
90 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Donenberg Philip B |
CFO, Treasurer and Secretary |
• – – |
2006-03-27 |
4 |
D |
$3.83 |
$120,032 |
D/D |
(31,340) |
34,822 |
|
- |
|
| Donenberg Philip B |
CFO, Treasurer and Secretary |
• – – |
2006-03-27 |
4 |
OE |
$2.30 |
$120,032 |
D/D |
52,188 |
66,162 |
|
- |
|
| Simes Stephen M |
Vice Chairman, President & CEO |
• • – |
2006-03-27 |
4 |
D |
$3.83 |
$231,439 |
I/I |
(60,428) |
109,688 |
|
- |
|
| Simes Stephen M |
Vice Chairman, President & CEO |
• • – |
2006-03-27 |
4 |
OE |
$2.30 |
$231,437 |
I/I |
100,625 |
170,116 |
|
- |
|
| Bell Steven J |
VP Research & Pre-Clinical Dev |
• – – |
2005-04-21 |
4 |
S |
$3.97 |
$5,555 |
D/D |
(1,400) |
875 |
|
- |
|
| Bell Steven J |
VP Research & Pre-Clinical Dev |
• – – |
2005-04-21 |
4 |
S |
$4.00 |
$2,000 |
D/D |
(500) |
2,275 |
|
- |
|
| Bell Steven J |
VP Research & Pre-Clinical Dev |
• – – |
2005-04-20 |
4 |
S |
$4.00 |
$6,400 |
D/D |
(1,600) |
2,775 |
|
- |
|
| Lehman Leah M |
Vice President, Prod. Dev. |
• – – |
2005-04-19 |
4 |
S |
$3.71 |
$139,379 |
D/D |
(37,000) |
0 |
|
- |
|
| Lehman Leah M |
Vice President, Prod. Dev. |
• – – |
2005-04-18 |
4 |
S |
$3.74 |
$163,260 |
D/D |
(43,000) |
37,000 |
|
- |
|
| Lehman Leah M |
Vice President, Prod. Dev. |
• – – |
2005-04-15 |
4 |
S |
$4.02 |
$1,516 |
D/D |
(377) |
80,000 |
|
- |
|
| Lehman Leah M |
Vice President, Prod. Dev. |
• – – |
2005-04-14 |
4 |
S |
$4.02 |
$118,467 |
D/D |
(29,400) |
80,377 |
|
- |
|
| Bell Steven J |
VP Research & Pre-Clinical Dev |
• – – |
2005-04-13 |
4 |
S |
$4.10 |
$410 |
D/D |
(100) |
4,375 |
|
- |
|
| Bell Steven J |
VP Research & Pre-Clinical Dev |
• – – |
2005-04-12 |
4 |
S |
$4.14 |
$2,068 |
D/D |
(500) |
4,475 |
|
- |
|
| Bell Steven J |
VP Research & Pre Clinical Dev |
• – – |
2005-04-12 |
4 |
S |
$4.12 |
$14,420 |
D/D |
(3,500) |
4,975 |
|
- |
|
| Bell Steven J |
VP Research & Pre Clinical Dev |
• – – |
2005-04-11 |
4 |
S |
$4.21 |
$22,714 |
D/D |
(5,400) |
8,475 |
|
- |
|
| Bell Steven J |
VP Research & Pre Clinical Dev |
• – – |
2005-04-11 |
4 |
OE |
$2.90 |
$36,250 |
D/D |
12,500 |
13,875 |
|
- |
|
| Mangano Ross J |
Director |
– • • |
2005-01-04 |
4 |
B |
$5.02 |
$150,588 |
I/I |
30,000 |
30,000 |
2.25 |
- |
|
| Perceptive Advisors Llc |
10% Owner |
– – • |
2004-12-03 |
4 |
S |
$4.35 |
$6,558,225 |
I/I |
(1,395,000) |
209,100 |
|
- |
|
| Mangano Ross J |
Director |
– • • |
2004-12-03 |
4 |
B |
$4.50 |
$90,000 |
D/D |
20,000 |
56,956 |
3.92 |
- |
|
| Perceptive Advisors Llc |
10% Owner |
– – • |
2004-12-02 |
4 |
S |
$4.47 |
$1,798,000 |
I/I |
(400,000) |
1,604,100 |
|
- |
|
| Perceptive Advisors Llc |
10% Owner |
– – • |
2004-12-02 |
4 |
B |
$3.98 |
$7,960 |
I/I |
2,000 |
1,877,650 |
1.5 |
- |
|
| Simes Stephen M |
V. Chair., Pres. & CEO |
• • – |
2004-11-30 |
4 |
S |
$10.07 |
$503,500 |
D/D |
(50,000) |
66,879 |
|
- |
|
| Simes Stephen M |
V. Chair., Pres. & CEO |
• • – |
2004-11-30 |
4 |
D |
$10.44 |
$174,003 |
D/D |
(16,667) |
116,879 |
|
- |
|
| Simes Stephen M |
V. Chair., Pres. & CEO |
• • – |
2004-11-30 |
4 |
OE |
$2.90 |
$174,000 |
D/D |
60,000 |
133,546 |
|
- |
|
| Lehman Leah M |
VP, Clinical & Reg. Affairs |
• – – |
2004-11-30 |
4 |
S |
$10.07 |
$503,500 |
D/D |
(50,000) |
109,777 |
|
- |
|
722 Records found
|
|
Page 25 of 29 |
|
|
0.14 (0.21%) 
